Answers are grounded in this paper and cite their sources.
Population-based cohort study reports improved survival with chemotherapy in stage III colon cancer, suggesting age impacts treatment outcomes.
e13778 Background: The magnitude of survival benefit associated with perioperative chemotherapy after resection for stage III colon cancer may vary by age in real-world practice due to differential treatment selection. We examined age-stratified associations of chemotherapy with overall and cause-specific mortality in a population-based cohort. Methods: SEER 2004–2015 resected AJCC6 stage III colon cancer. Treatment: surgery+chemotherapy vs surgery only (no/unknown chemo). Multivariable Cox models with age interaction estimated age-stratified HRs for OS. Cause-specific and non–cancer-specific death were evaluated using cause-specific Cox models. Results: Among 72,297 patients, 57.5% received surgery+chemo (41,584) and 42.5% surgery-only (30,713). The chemo group was markedly younger (age ≥80: 9.2% vs 43.0%) and less often widowed (12.6% vs 30.5%); sex and grade were similar, and stage mix was comparable (IIIB most common; IIIC ~35% vs 32%). Chemotherapy was associated with improved OS in all age groups with a consistent U-shaped pattern: HRs were higher in younger patients (45–49: 0.82, 95% CI 0.72–0.92; 50–54: 0.80, 0.73–0.88), decreased to a nadir in the 70s (70–74: 0.56, 0.53–0.58; 75–79: 0.56, 0.53–0.58), then attenuated in older strata (80–84: 0.60, 0.57–0.63; ≥90: 0.64, 0.52–0.78). This non-monotonic age pattern was preserved across AJCC6 IIIA/IIIB/IIIC subgroups (lowest HR typically ~70–79, with wider CIs at extremes). In competing-risk analyses, surgery+chemo was associated with lower hazards of both cancer death (HR range ~0.59–0.86; e.g., 75–79: 0.58, 0.55–0.62; ≥90: 0.75, 0.59–0.96) and non-cancer death (HR range ~0.51–0.62; e.g., 70–74: 0.52, 0.48–0.56; 75–79: 0.52, 0.49–0.56). Conclusions: Perioperative chemotherapy was associated with improved OS and reduced cancer and non-cancer mortality across ages, but the magnitude was non-monotonic—strongest in patients ~70–79 and attenuated at younger and very old extremes—consistent with substantial age-dependent treatment selection in observational data.
No takes yet. Share an insight, caveat, or question.
Leeseul Kim (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: